Drug Trial Radar · NCT07377721
A Study of HRS-2129 in Patients With Diabetic Peripheral Neuropathic Pain
Last checked: Nov 19, 2026Latest source record: Apr 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
168
Planned (sponsor's estimate)
Start
Mar 24, 2026
Primary completion
Sep 2026
Study completion Nov 2026
Sponsor
- Lead sponsor
- Shandong Suncadia Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 30, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to investigate the efficacy and safety of HRS-2129 in Chinese diabetic peripheral neuropathic pain (DPNP) in comparison to placebo.
Conditions
- Diabetic Peripheral Neuropathic Pain
Interventions
HRS-2129 TabletsDrug
HRS-2129 tablets.
HRS-2129 PlaceboDrug
HRS-2129 placebo.
Pregabalin CapsulesDrug
Pregabalin capsules.
Pregabalin Capsules PlaceboDrug
Pregabalin capsules placebo.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Compare the change from baseline in Average Daily Pain Score (ADPS) between HRS-2129 and placebo at Week 4.Time frame: Baseline and Week 4.
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
China-Japan Friendship Hospital
Beijing, Beijing Municipality, China · Recruiting
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.